TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04224493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Stage 1 (Phase 1b):~Tazemetostat was escalated from a starting dose of 400 mg orally twice daily to 600 mg orally twice daily to 800 mg PO twice daily in 28-day cycles as tolerated in a standard 3 + 3 design. Tazemetostat will be administered as monotherapy at an 800 mg twice daily dose for up to 2 years after the initial 12 months of combination therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Stage 2:~Tazemetostat 800 mg administered orally twice daily in continuous 28-day cycles for 12 cycles. Tazemetostat will be administered as monotherapy at an 800 mg twice daily dose for up to 2 years after the initial 12 months of combination therapy.
Study: NCT03068858

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: real-time feedback of SYNTAX score category
Study: NCT02618239

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bimuno Galacto-oligo-saccharide
Study: NCT02953080

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Call for life mHealth adherence support
Description: Daily/ weekly pill reminder support Health Info-tips Appointment visit reminders Self-reported symptom support
Study: NCT01273844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib
Study: NCT01799148

Intervention type: OTHER
Intervention: Particulate air pollutants
Description: We will determined the average concentrations of different sizes of particulate matter from 1 day or up to 7 days prior to admission in patients with acute coronary syndrome.
Study: NCT02558218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane Ultra
Description: Further to standard medication (tobradex quid for 20 days), participants were administered Systane Ultra quid for 2 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tobradex quid (Standard)
Description: Standard medication (tobradex quid for 20 days)
Study: NCT03747354

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: blood samples
Description: blood samples

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: blood samples
Description: blood samples
Study: NCT04060537

Intervention type: OTHER
Intervention: Laboratory analysis of samples
Description: RNA sequencing, immunohistochemistry, immunofluorescence, and cytometry of tumour tissues

Intervention type: OTHER
Intervention: Application of machine learning
Description: Using machine learning to interrogate data generated from analysis of Renal Cell Cancer tumours using RNA sequencing, immunohistochemistry, immunofluorescence, cytometry, and MRI imaging of tumours.
Study: NCT04323358

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Biometry
Description: Patients will be asked to place the chin in position and open their eyes wide. In between measurements, the patient will be arranged so his eyes are in one horizontal line and each time before measurement the patient will be asked to blink several times.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Biometry
Description: Patients will be asked to place the chin in position and open their eyes wide. In between measurements, the patient will be arranged so his eyes are in one horizontal line and each time before measurement the patient will be asked to blink several times.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Keratometry
Description: Patients will be asked to place the chin in position and open their eyes wide. In between measurements, the patient will be arranged so his eyes are in one horizontal line and each time before measurement the patient will be asked to blink several times.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Keratometry
Description: Patients will be asked to place the chin in position and open their eyes wide. In between measurements, the patient will be arranged so his eyes are in one horizontal line and each time before measurement the patient will be asked to blink several times.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Keratometry
Description: Patients will be asked to place the chin in position and open their eyes wide. In between measurements, the patient will be arranged so his eyes are in one horizontal line and each time before measurement the patient will be asked to blink several times.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Keratometry
Description: Patients will be asked to place the chin in position and open their eyes wide. In between measurements, the patient will be arranged so his eyes are in one horizontal line and each time before measurement the patient will be asked to blink several times.
Study: NCT01511471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 90mg twice a day for 15 days
Study: NCT03272113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SKIP-IT
Description: A theory-based intervention using narrative, images and embedded behaviour change techniques, delivered via text-messaging.
Study: NCT03050788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone confocal microscopy
Description: Imaging of skin lesion using the smartphone confocal microscopy
Study: NCT04048018

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw and IGRA test
Description: One to two blood samples will be obtained from participants in all arms in order to conduct testing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw and IGRA test
Description: One to two blood samples will be obtained from participants in all arms in order to conduct testing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw and IGRA test
Description: One to two blood samples will be obtained from participants in all arms in order to conduct testing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw and IGRA test
Description: One to two blood samples will be obtained from participants in all arms in order to conduct testing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw and IGRA test
Description: One to two blood samples will be obtained from participants in all arms in order to conduct testing.
Study: NCT03390569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The patients meet with a registered physiotherapist and receive individualized exercise programs starting the second week of treatment, and continuing up to 3 months later.
Study: NCT00367991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human erythropoietin alfa (drug)
Description: 200 U/kg IV daily for 3 days vs. matched volume of normal saline IV daily for 3 days
Study: NCT03443843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Fluticasone Propionate Nasal Spray 50mcg per spray, 2 sprays per nostril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo spray
Description: Placebo Nasal Spray, 2 sprays per nostril
Study: NCT00367991

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline to match active drug (rHuEpo)
Study: NCT00354406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abciximab
Description: standard i.v. bolus of abciximab is administered at time of randomization in arm A, and at time of primary angioplasty in arm B.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abciximab
Description: standard i.v. bolus of abciximab is administered at time of randomization in arm A, and at time of primary angioplasty in arm B.
Study: NCT02770599

Intervention type: OTHER
Intervention: IBD multidisciplinary team model including IBD nurse
Description: IBD multidisciplinary team model including IBD nurse
Study: NCT02203630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock
Study: NCT01269736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Online ECG monitoring education program and strategies to implement and sustain change for nurses
Study: NCT03343938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embryo handling in a closed station
Description: Embryo handling is performed inside a closed station with a controlled environment: 6% CO2 and 37 degrees.
Study: NCT00980135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sinecort cream
Description: Application over 29 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortison cream
Description: Application over 29 days

Intervention type: OTHER
Group type: OTHER
Intervention: Untreated skin
Study: NCT03443843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo spray
Description: Placebo Nasal Spray, 2 sprays per nostril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo spray
Description: Placebo Nasal Spray, 2 sprays per nostril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo spray
Description: Placebo Nasal Spray, 2 sprays per nostril
Study: NCT04970524

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comparison of conventional free gingival graft versus partial free gingival graft
Description: Conventional free gingival graft was applied to the area of the patient with attached gingival insufficiency determined by randomization.~Clinical and aesthetic comparisons were made in the postoperative 1st, 3rd and 6th months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comparison of conventional free gingival graft versus partial free gingival graft
Description: Partially de-epithelialized free gingival graft was applied to the other region of the patient with attached gingival insufficiency determined by randomization.~Clinical and aesthetic comparisons were made in the postoperative 1st, 3rd and 6th months.
Study: NCT01795898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl transdermal patches releasing 12.5 microgram of fentanyl will be applied for 3 days. The patches will be replaced every 3 days (Day 3, 7 and 10).
Study: NCT04523064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25 MG
Description: Patients with diabetes waiting for surgery will receive empagliflozin for at least three months.
Study: NCT04813848

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of varnish fluoride desensitizing agent on buccal surfaces of exposed dentin
Description: Varnish fluoride is a single dose transparent varnish with 5 % sodium fluoride (22.600 ppm fluoride) and 5 % calcium fluoride.~The application was performed according to the manufacturer's instructions. The varnish was applied on a clean and dry surface, then after 10-20 seconds to allow the fluoride varnish to be absorbed, was then dried with air.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Application of bonding agent desensitizing agent on buccal surfaces of exposed dentin
Description: Bonding agent is a single dose dual curing universal adhesive and its application was performed according to the manufacturer's instruction for cases with hypersensitive tooth necks. The bonding was applied without etching, on a clean and dry surface. After 10 s any excess material was removed and then light cured for 30 s.
Study: NCT02308345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-chemotherapy visit summary Video
Study: NCT02007330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic intravenous lidocaine infusion
Description: In group L, intravenous lidocaine infusion (0.1mg/kg) for 1minutes after induction of anesthesia. After 1 minutes, lidocaine infusion continued at rate of 1.5mg/kg/hr during operation, and discontinued before move the patients to PACU.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline infusion
Description: In group C, the patients receive same volume of normal saline
Study: NCT00824187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE20/DRSP(YAZ, BAY86-5300)
Description: 20 μg ethinylestradiol, 3mg drospirenone, tablet, orally, opd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert tablet
Study: NCT01583998

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: e-MBC
Description: antidepressant treatment
Study: NCT02638805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650 Osmotic Mini Pump 20/60 mcg/day
Description: ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650 Osmotic Mini Pump 60 mcg/day
Description: ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Stable dose for at least 3 months (at least 1000 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Stable dose for at least 3 months (at least 1000 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Stable dose for at least 3 months (at least 1.2 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Stable dose for at least 3 months (at least 1.2 mg/day)
Study: NCT02145091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moderately-high dose of psilocybin
Description: Oral dose of a moderately-high dose of psilocybin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moderately-high dose of psilocybin
Description: Oral dose of a moderately-high dose of psilocybin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moderately-high dose of psilocybin
Description: Oral dose of a moderately-high dose of psilocybin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moderately-low dose of psilocybin
Description: Oral dose of a moderately-low dose of psilocybin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Very-low dose of psilocybin
Description: Oral dose of a very-low dose of psilocybin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: An oral placebo (lactose pill).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: An oral placebo (lactose pill).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: An oral placebo (lactose pill).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: An oral placebo (lactose pill).
Study: NCT03765476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SALIENCE
Description: 3 computer-based training sessions with program SALIENCE per week over 3 weeks (see study description)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: treatment as usual, , i.e. medically supervised detoxification treatment (i.e. medical management of withdrawal symptoms, associated physical discomfort and any co-existing disorders, etc.) as well as health education and supportive therapy sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU
Description: treatment as usual, , i.e. medically supervised detoxification treatment (i.e. medical management of withdrawal symptoms, associated physical discomfort and any co-existing disorders, etc.) as well as health education and supportive therapy sessions.
Study: NCT02077634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abiraterone acetate + prednisone + LHRH-therapy
Description: Hormon therapy will go on

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abiraterone acetate + prednisone
Description: ormon therapy will be stopped
Study: NCT00114283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03571334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (Xeomin®, Merz) (INA)
Description: IncobotulinumtoxinA (Xeomin®, Merz) (INA) will be reconstituted with preservative-free normal saline to a dilution of 5mL:100 units. Study participants will receive 50u INA (total volume 2.5mL) injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.) Study participants will receive one series of injections during the trial. In the hands, INA will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). In the feet, INA will be injected across the dorsal surface of the foot in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). Injections will be performed intradermally using a 5/16-inch, 32-g needle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Study participants will total volume 2.5mL of 0.9% Normal saline injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.) Study participants will receive one series of injections during the trial. In the hands, 0.9% Normal saline will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). In the feet, 0.9% Normal saline will be injected across the dorsal surface of the foot in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). Injections will be performed intradermally using a 5/16-inch, 32-g needle
Study: NCT03898336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: broad-spectrum micronutrient
Description: daily intake of capsules containing a blend of Vitamin B3 (NADH), Vitamin B6 (pyridoxal-5-phosphate), folic acid (5-MTHF), Vitamin B12 (methylcobalamin), Vitamin D3 (25-hydroxyvitamin D3), Magnesium (magnesium oxide), Zinc (zinc methionine), Iron (ferric phosphate), Selenium (selenomethionine), Phospholipids, L-carnitine (L-carnitine-L-tartrate)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: daily intake of capsules
Study: NCT01272297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LI-ESWT
Description: Low intensity shock wave treatment - 12 sessions
Study: NCT03105206

Intervention type: PROCEDURE
Intervention: Flexible Ureteroscopy
Description: the Treatment of Low Pole Renal Calculus by Flexible Ureteroscope
Study: NCT00869765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: 100 mg D-cycloserine once every weekday taken 2 hours before tDCS session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS (Eldith DC-Stimulator (CE certified))
Description: tDCS session lasting continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
Study: NCT02014935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low intensity laser
Description: The study wants to evaluate the use of low intensity laser on the spastic muscle.~Want to assess whether the Low level laser prove change in muscle performace of the individual but also alters muscle activity and blood lactate.
Study: NCT05595785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical-Based Yoga Practice
Description: Physical-based yoga classes emphasized Bishnu Ghosh lineage hatha yoga. The 50 minute yoga classes were twice per week for four weeks. The yoga instructor had certifications in both Bikram and Amrit yoga practices and training in Bishnu Ghosh lineage hatha yoga as taught by Mary Jarvis

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Yoga Practice
Description: The mindfulness-based yoga classes included all elements of the physical-based yoga classes with the addition of mindfulness cues. The mindfulness cues included body scan, mindful movement, and yoga nidra. Certification of the instructor included the Integrative Amrit Method of Yoga Nidra that was inclusive of the use of mindfulness cues that coincided with the physical postures of yoga.
Study: NCT04030104

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reader Study - Imagio Ultrasound
Description: Imagio ultrasound images to be reviewed as part of Reader study
Study: NCT04370431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radicut® (bag) , 60 mg
Description: An intravenous dose of edaravone injection, containing 30 mg edaravone in a 100 mL injection bag, will be administered at a dose of 60 mg over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radicut® (bag) , 60 mg
Description: An intravenous dose of edaravone injection, containing 30 mg edaravone in a 100 mL injection bag, will be administered at a dose of 60 mg over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTYP01, up to 120 mg
Description: TTYP01 oral tablets (30 mg edaravone per tablet). The fixed oral dose level of TTYP01 will depend on the results obtained in Part B of the study (no more than 120 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTYP01, up to 120 mg
Description: TTYP01 oral tablets (30 mg edaravone per tablet). The fixed oral dose level of TTYP01 will depend on the results obtained in Part B of the study (no more than 120 mg)
Study: NCT01510860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UDCA (Ursodeoxycholic acid)
Description: 250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA (Ursodeoxycholic acid)
Description: 500 mg
Study: NCT00468793

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous fluid
Description: The same intravenous fluids will be used in both arms but the volume will be different

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fluid
Description: The same intravenous fluids will be used in both arms but the volume will be different
Study: NCT01067716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STAR S4IR LASIK with VSS-R ablation profile
Description: LASIK treatment targeted for emmetropia